COMPANY

Brixton Biosciences, Inc.

HQ: Cambridge, MA source · brixtonbio.com ↗ · New England

Also known as Brixton Biosciences · 6 sources

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Greater Trochanteric Pain Syndrome Greater Trochanteric Pain Syndrome of Both Lower Limbs Lateral Hip Pain Osteoarthritis (OA) of the Knee

Timeline

Aug 21, 2026 FDA FDA De Novo grant: ReneuRx (Neural Ice) — DEN250067, Aug 21, 2026. Applicant at approval: Brixton Biosciences. source ↗
Jul 27, 2026 Trial start Not phased (device or behavioral study): ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain source ↗
Aug 7, 2025 Grant Government grant — SBIR: $1.05M (annual award, as published), announced Aug 7, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗
Nov 19, 2024 Trial start Not phased (device or behavioral study): INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE source ↗

Feb 1, 2027 (ESTIMATED) · Not phased · INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE · NCT06700109
Nov 1, 2027 (ESTIMATED) · Not phased · ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain · NCT07568015

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Aug 7, 2025 Government grant — SBIR: $1.05M (annual award, as published), announced Aug 7, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07568015	ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain	Not phased (device or behavioral study)	Recruiting	Jul 27, 2026	Nov 1, 2027 (estimated)
NCT06700109	INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE	Not phased (device or behavioral study)	Active, not recruiting	Nov 19, 2024	Feb 1, 2027 (estimated)

Aug 21, 2026 FDA De Novo grant: ReneuRx (Neural Ice) — DEN250067, Aug 21, 2026. Applicant at approval: Brixton Biosciences. source ↗

Annual award amounts. Total $1.3M.

Aug 21, 2024 NIH award 1R44AR084998-01 FY2024: $998,787 awarded for that fiscal year; activity R44 (SBIR); PI SIDOTI, CHARLES; recipient as written: BRIXTON BIOSCIENCES, INC., Cambridge, MA. Neural Ice Technology for Treatment of source ↗
Sep 27, 2022 NIH award 1R41AR080620-01A1 FY2022: $252,130 awarded for that fiscal year; activity R41 (STTR); PI SIDOTI, CHARLES; recipient as written: BRIXTON BIOSCIENCES, INC., Cambridge, MA. Injectable Ice Slurry Cooling Techno source ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12